149 related articles for article (PubMed ID: 30890317)
1. Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms.
Winoker JS; Say RK; Mehrazin R; Stock RG; Stone NN
Brachytherapy; 2019; 18(3):332-337. PubMed ID: 30890317
[TBL] [Abstract][Full Text] [Related]
2. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
[TBL] [Abstract][Full Text] [Related]
3. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? : A prospective, randomized, controlled trial.
Yan M; Xue P; Wang K; Gao G; Zhang W; Sun F
Strahlenther Onkol; 2017 Sep; 193(9):714-721. PubMed ID: 28612083
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer.
Yu YD; Kang MH; Choi CI; Shin HS; Oh JJ; Park DS
World J Urol; 2016 Sep; 34(9):1269-74. PubMed ID: 26868648
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
8. The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer.
Blaivas JG; Weiss JP; Jones M
BJU Int; 2006 Dec; 98(6):1233-7; discussion 1237. PubMed ID: 17125481
[TBL] [Abstract][Full Text] [Related]
9. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms.
Cho S; Kwon SS; Lee KW; Yoo TK; Shin DG; Kim SW; Bae JH; Choi H; Kim YH
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508455
[TBL] [Abstract][Full Text] [Related]
10. [Interest of a systematic assessment of the treatment of the lower urinary tract symptoms in the management of benign prostatic hypertrophy in general practice (1380 patients) - Study EVALURO].
Descazeaud A; Coloby P; De La Taille A; Kouri G; Mallet R; Rossi D; Rozet F; Zerbib M; Carrois F
Prog Urol; 2019 Feb; 29(2):116-126. PubMed ID: 30665818
[TBL] [Abstract][Full Text] [Related]
11. High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores.
Morgan TM; Rossi PJ; Cutrell PK; Zhang C; Press RH; Rahnema S; Sanda M; Pattaras J; Cimmino C; Hershatter B; Jani AB; Patel PR
Brachytherapy; 2019; 18(6):793-799. PubMed ID: 31337543
[TBL] [Abstract][Full Text] [Related]
12. Decline in acute urinary toxicities with increased institutional experience: 15-year experience of permanent seed prostate brachytherapy in a single Australasian institution.
Ong WL; Matheson B; Millar J
Brachytherapy; 2017; 16(2):313-322. PubMed ID: 28017293
[TBL] [Abstract][Full Text] [Related]
13. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.
Fujimura T; Kume H; Nishimatsu H; Sugihara T; Nomiya A; Tsurumaki Y; Miyazaki H; Suzuki M; Fukuhara H; Enomoto Y; Homma Y
BJU Int; 2012 May; 109(10):1512-6. PubMed ID: 21883834
[TBL] [Abstract][Full Text] [Related]
14. Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience.
Ito M; Makita C; Mori T; Takano H; Kumano T; Matsuo M; Iinuma K; Kawase M; Nakane K; Nakano M; Koie T
Curr Oncol; 2023 Jun; 30(6):5680-5689. PubMed ID: 37366909
[TBL] [Abstract][Full Text] [Related]
15. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
Porst H; Oelke M; Goldfischer ER; Cox D; Watts S; Dey D; Viktrup L
Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
[TBL] [Abstract][Full Text] [Related]
17. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
Lehrer S; Cesaretti J; Stone NN; Stock RG
BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
[TBL] [Abstract][Full Text] [Related]
18. Temporal resolution of urinary morbidity following prostate brachytherapy.
Merrick GS; Butler WM; Lief JH; Dorsey AT
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
[TBL] [Abstract][Full Text] [Related]
19. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.
Jhang JF; Liao CH; Kuo HC
Int J Clin Pract; 2014 Jun; 68(6):743-8. PubMed ID: 24471413
[TBL] [Abstract][Full Text] [Related]
20. Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
Teishima J; Iwamoto H; Miyamoto K; Shoji K; Masumoto H; Inoue S; Kobayashi K; Kajiwara M; Matsubara A
Int J Urol; 2012 Dec; 19(12):1083-9. PubMed ID: 22852805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
